Elevated human epididymis protein 4 concentrations in chronic kidney disease

Annals of Clinical Biochemistry

Volumn 49, Issue 4, 2012, Pages 377-380

  Nagy, Béla ^a   Krasznai, Zoárd T ^a   Balla, Heidi ^a   Csobán, Mária ^a   Antal Szalmás, Péter ^a   Hernádi, Zoltán ^a   Kappelmayer, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CREATININE; HUMAN EPIDIDYMIS PROTEIN 4; UREA;

ADULT; ARTICLE; CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ELECTROCHEMILUMINESCENT IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OVARY FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EPIDIDYMIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE;

EID: 84867135897     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011258     Document Type: Article

References (19)

1. Seibaek L, Petersen LK, Blaakaer J, Hounsgaard L. Symptom interpretation and health care seeking in ovarian cancer. BMC Womens Health 2011;11:31
2. Bamias A, Karadimou A, Soupos N, et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/ paclitaxel chemotherapy: a single institution experience. Gynecol Oncol 2011;123:37-42
3. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87
4. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist 1997;2:6-9
5. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53
6. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700
7. Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15:274-81
8. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6
9. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010;116:378-83
10. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5
11. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9
12. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9
13. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280-8
14. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-44
15. Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011;32:265-71
16. Anastasi E, Granato T, Marchei GG, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010;31:411-5
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266
18. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996;106:118-23
19. Wayand D, Baum H, Schätzle G, Schärf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000;46:1345-50